CSIMarket



Best Performing Stocks In Major Pharmaceutical Preparations Industry Over The Past 12 Months



 1 Day   Week  Current Month of July  30 Days 
Current Quarter Q3 of 2024  90 Days    Ytd    12 Months 
 

Shares increased by 7.83% on average, in Major Pharmaceutical Preparations Industry over the past 12 months.

Here are the best performing stocks in Major Pharmaceutical Preparations Industry.




BNTC

$9.47

$9.2500 4,204.55%
Last 12 Months


BNTC

$9.47

$9.2500 4,204.55%



Benitec Biopharma Inc

Benitec Biopharma Inc shares improved 4,204.55% over the past 12 months.


Benitec Biopharma Inc is a biotechnology company that focuses on developing and commercializing gene therapy products. They utilize their proprietary RNA interference technology to target and silence disease-causing genes, ultimately aiming to provide effective treatment options for various genetic diseases.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 24.776 mill. $ - mill. $ -21.692 mill. 3 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 24.776 mill.


$ - mill.


$ -21.692 mill.

Employees Shares Outstanding P/E

-


3 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



VCNX

$6.575

$6.2597 1,985.32%
Last 12 Months


VCNX

$6.575

$6.2597 1,985.32%



Vaccinex Inc

Vaccinex Inc shares improved 1,985.32% over the past 12 months.


Vaccinex Inc operates on a biopharmaceutical business model, focusing on the development and commercialization of antibody-based therapies. The company utilizes its proprietary ActivMAb? Antibody Discovery Technology to discover and develop novel antibody therapeutics for the treatment of various diseases. Vaccinex collaborates with strategic partners and pharmaceutical companies to advance the clinical development and commercialization of its product candidates.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 29.632 mill. $ 0.795 mill. $ 2.765 mill. 5 mill. - Y/Y -60.00 %
Market Cap. Revenues TTM Net Income TTM

$ 29.632 mill.


$ 0.795 mill.


$ 2.765 mill.

Employees Shares Outstanding P/E

-


5 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -60.00 %


MRQ Y/Y - %



UPC

$3.3

$2.9300 791.89%
Last 12 Months


UPC

$3.3

$2.9300 791.89%



Universe Pharmaceuticals Inc

Universe Pharmaceuticals Inc shares increased 791.89% over the past 12 months.


Universe Pharmaceuticals Inc is a pharmaceutical company that follows a business model focused on research, development, and manufacturing of medications. They aim to identify and address unmet medical needs by developing innovative pharmaceutical products. Through strategic partnerships and collaborations, they strive to bring their products to market and provide effective healthcare solutions to patients worldwide.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 11.963 mill. $ 32.309 mill. $ -6.163 mill. 4 mill. - Y/Y -19.52 %
Market Cap. Revenues TTM Net Income TTM

$ 11.963 mill.


$ 32.309 mill.


$ -6.163 mill.

Employees Shares Outstanding P/E

-


4 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -19.52 %


MRQ Y/Y - %



SKVI

$0.69

$0.6089 750.80%
Last 12 Months


SKVI

$0.69

$0.6089 750.80%



Skinvisible Inc

Skinvisible Inc stock went up 750.80% over the past 12 months.


Skinvisible Inc*s business model revolves around the development, licensing, and sale of innovative and patented skincare technologies and formulations for use in various consumer and pharmaceutical applications.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 3.132 mill. $ 0.020 mill. $ -1.158 mill. 5 mill. - Y/Y 0.00 %
Market Cap. Revenues TTM Net Income TTM

$ 3.132 mill.


$ 0.020 mill.


$ -1.158 mill.

Employees Shares Outstanding P/E

-


5 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 0.00 %


MRQ Y/Y - %



CRBP

$58.9

$50.9500 640.88%
Last 12 Months


CRBP

$58.9

$50.9500 640.88%



Corbus Pharmaceuticals Holdings Inc

Corbus Pharmaceuticals Holdings Inc stock increased 640.88% over the past 12 months.


Corbus Pharmaceuticals Holdings Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for inflammatory and fibrotic diseases. Their business model revolves around conducting research and clinical trials to identify potential drug candidates, obtaining regulatory approvals, and subsequently commercializing these drugs to generate revenue. They aim to address unmet medical needs by creating and marketing novel treatments for diseases such as systemic sclerosis, cystic fibrosis, and other inflammatory conditions.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 260.551 mill. $ - mill. $ -47.461 mill. 4 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 260.551 mill.


$ - mill.


$ -47.461 mill.

Employees Shares Outstanding P/E

57


4 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



LBPH

$36.83

$29.9700 436.88%
Last 12 Months


LBPH

$36.83

$29.9700 436.88%



Longboard Pharmaceuticals Inc

Longboard Pharmaceuticals Inc stock went up 436.88% over the past 12 months.


Longboard Pharmaceuticals Inc is a biotechnology company focused on the discovery and development of therapies for neurological disorders. Their business model revolves around conducting comprehensive research, identifying promising drug candidates, and advancing them through preclinical and clinical trials. With a focus on innovative approaches and strategic partnerships, Longboard aims to ultimately bring safe and effective treatments to patients in need.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 865.043 mill. $ - mill. $ -50.734 mill. 23 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 865.043 mill.


$ - mill.


$ -50.734 mill.

Employees Shares Outstanding P/E

-


23 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



EDSA

$4.26

$3.4482 424.76%
Last 12 Months


EDSA

$4.26

$3.4482 424.76%



Edesa Biotech Inc

Edesa Biotech Inc stock went up 424.76% over the past 12 months.


Edesa Biotech Inc*s business model focuses on the development and commercialization of innovative therapeutics in the field of dermatology and gastrointestinal diseases.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 13.601 mill. $ - mill. $ -7.245 mill. 3 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 13.601 mill.


$ - mill.


$ -7.245 mill.

Employees Shares Outstanding P/E

-


3 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



ETST

$0.2479

$0.1980 396.79%
Last 12 Months


ETST

$0.2479

$0.1980 396.79%



Earth Science Tech Inc

Earth Science Tech Inc stock increased 396.79% over the past 12 months.


Earth Science Tech Inc is a biotechnology company focused on developing and marketing innovative hemp cannabinoid-based products. Their business model revolves around research, development, manufacturing, and distribution of high-quality CBD and nutraceuticals for various industries, including the pharmaceutical and nutrition sectors.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 67.110 mill. $ 11.954 mill. $ 0.812 mill. 271 mill. 331,164,306.34 Y/Y 13,875.49 %
Market Cap. Revenues TTM Net Income TTM

$ 67.110 mill.


$ 11.954 mill.


$ 0.812 mill.

Employees Shares Outstanding P/E

-


271 mill.


331,164,306.34

Revenue Growth Income Growth

MRQ Y/Y 13,875.49 %


MRQ Y/Y - %



GOVX

$2.78

$2.1893 370.63%
Last 12 Months


GOVX

$2.78

$2.1893 370.63%



Geovax Labs Inc

Geovax Labs Inc shares improved 370.63% over the past 12 months.


Geovax Labs Inc*s business model primarily focuses on the development and commercialization of innovative vaccines to prevent and treat diseases, with a particular emphasis on HIV/AIDS. They aim to bridge the gap in preventing and managing these diseases through their vaccine candidates and strategic partnerships.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 6.580 mill. $ - mill. $ -24.224 mill. 2 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 6.580 mill.


$ - mill.


$ -24.224 mill.

Employees Shares Outstanding P/E

-


2 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



ELTP

$0.1788

$0.1403 364.42%
Last 12 Months


ELTP

$0.1788

$0.1403 364.42%



Elite Pharmaceuticals Inc

Elite Pharmaceuticals Inc shares improved 364.42% over the past 12 months.


Elite Pharmaceuticals Inc. is a pharmaceutical company that specializes in developing and manufacturing generic and abuse-deterrent controlled-release products. Their business model focuses on conducting research, obtaining regulatory approvals, and licensing their products to other pharmaceutical companies for commercialization and distribution.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 179.771 mill. $ 56.357 mill. $ 20.109 mill. 1,005 mill. 11.30 Y/Y 127.93 %
Market Cap. Revenues TTM Net Income TTM

$ 179.771 mill.


$ 56.357 mill.


$ 20.109 mill.

Employees Shares Outstanding P/E

67


1,005 mill.


11.30

Revenue Growth Income Growth

MRQ Y/Y 127.93 %


MRQ Y/Y - %



RNA

$44.8

$33.7200 304.33%
Last 12 Months


RNA

$44.8

$33.7200 304.33%



Avidity Biosciences Inc

Avidity Biosciences Inc shares went up 304.33% over the past 12 months.


Avidity Biosciences Inc*s business model revolves around developing and commercializing potential therapeutics using its proprietary AOC platform, which enables the targeted delivery of drugs to specific cells in the body.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 3,907.098 mill. $ 10.870 mill. $ -228.681 mill. 87 mill. - Y/Y 58.67 %
Market Cap. Revenues TTM Net Income TTM

$ 3,907.098 mill.


$ 10.870 mill.


$ -228.681 mill.

Employees Shares Outstanding P/E

-


87 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 58.67 %


MRQ Y/Y - %



APLT

$5.55

$4.1700 302.17%
Last 12 Months


APLT

$5.55

$4.1700 302.17%



Applied Therapeutics Inc

Applied Therapeutics Inc stock went up 302.17% over the past 12 months.


Applied Therapeutics Inc is a pharmaceutical company that focuses on developing and commercializing novel therapies to treat metabolic diseases. They employ a combination of in-house research and external collaborations to identify and advance potential drug candidates through clinical trials and regulatory approvals.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 695.520 mill. $ -0.477 mill. $ -193.564 mill. 125 mill. - Y/Y -98.22 %
Market Cap. Revenues TTM Net Income TTM

$ 695.520 mill.


$ -0.477 mill.


$ -193.564 mill.

Employees Shares Outstanding P/E

-


125 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -98.22 %


MRQ Y/Y - %



ADIL

$1.13

$0.8398 289.39%
Last 12 Months


ADIL

$1.13

$0.8398 289.39%



Adial Pharmaceuticals Inc

Adial Pharmaceuticals Inc shares increased 289.39% over the past 12 months.


Adial Pharmaceuticals Inc is a biopharmaceutical company that specializes in developing medications for the treatment of alcohol use disorder. Their business model revolves around conducting clinical trials, obtaining regulatory approvals, and marketing their products to healthcare professionals and potential patients.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 1.332 mill. $ - mill. $ -6.070 mill. 1 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 1.332 mill.


$ - mill.


$ -6.070 mill.

Employees Shares Outstanding P/E

-


1 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



SMMT

$8.55

$6.3500 288.64%
Last 12 Months


SMMT

$8.55

$6.3500 288.64%



Summit Therapeutics Inc

Summit Therapeutics Inc stock improved 288.64% over the past 12 months.


Summit Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of rare diseases. The company employs a research-driven business model, leveraging its proprietary technologies and expertise to identify and develop novel drugs targeting specific genetic mutations associated with these rare diseases. Summit Therapeutics Inc aims to bring its drug candidates through preclinical and clinical development stages and ultimately secure regulatory approval and commercialize them to benefit patients in need.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 6,000.264 mill. $ - mill. $ -116.025 mill. 702 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 6,000.264 mill.


$ - mill.


$ -116.025 mill.

Employees Shares Outstanding P/E

70


702 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



BLTE

$49.16

$36.2200 279.91%
Last 12 Months


BLTE

$49.16

$36.2200 279.91%



Belite Bio Inc

Belite Bio Inc shares went up 279.91% over the past 12 months.


Belite Bio Inc*s business model involves leveraging biotechnology to develop and commercialize innovative solutions for various industries. They focus on creating sustainable and environmentally friendly products by harnessing the power of natural biological processes.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 1,307.345 mill. $ - mill. $ -31.632 mill. 27 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 1,307.345 mill.


$ - mill.


$ -31.632 mill.

Employees Shares Outstanding P/E

-


27 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



PCSA

$1.8

$1.3127 269.38%
Last 12 Months


PCSA

$1.8

$1.3127 269.38%



Processa Pharmaceuticals Inc

Processa Pharmaceuticals Inc shares improved 269.38% over the past 12 months.


Processa Pharmaceuticals Inc is a biopharmaceutical company that operates by developing and commercializing innovative drug candidates for various medical conditions. They focus on advancing treatments through clinical trials, obtaining regulatory approvals, and partnering with other healthcare organizations for distribution and marketing.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 4.440 mill. $ - mill. $ -7.827 mill. 2 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 4.440 mill.


$ - mill.


$ -7.827 mill.

Employees Shares Outstanding P/E

-


2 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



INSM

$76.71

$55.7400 265.81%
Last 12 Months


INSM

$76.71

$55.7400 265.81%



Insmed Inc

Insmed Inc stock went up 265.81% over the past 12 months.


Insmed Inc operates as a biopharmaceutical company focused on developing novel therapies for serious and rare diseases. The company*s business model revolves around discovering, developing, and commercializing innovative therapies to address significant unmet medical needs. Insmed Inc*s efforts primarily center around leveraging its expertise in biologics and advanced drug delivery technologies to improve the lives of patients with rare pulmonary diseases.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 11,388.060 mill. $ 319.709 mill. $ -746.894 mill. 148 mill. - Y/Y 22.27 %
Market Cap. Revenues TTM Net Income TTM

$ 11,388.060 mill.


$ 319.709 mill.


$ -746.894 mill.

Employees Shares Outstanding P/E

400


148 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 22.27 %


MRQ Y/Y - %



VKTX

$57.18

$41.4400 263.28%
Last 12 Months


VKTX

$57.18

$41.4400 263.28%



Viking Therapeutics Inc

Viking Therapeutics Inc shares increased 263.28% over the past 12 months.


Viking Therapeutics Inc is a biopharmaceutical company focused on the development of innovative therapies for metabolic and endocrine disorders.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 5,709.194 mill. $ - mill. $ -80.849 mill. 100 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 5,709.194 mill.


$ - mill.


$ -80.849 mill.

Employees Shares Outstanding P/E

11


100 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



DYN

$41.54

$30.0800 262.48%
Last 12 Months


DYN

$41.54

$30.0800 262.48%



Dyne Therapeutics Inc

Dyne Therapeutics Inc shares went up 262.48% over the past 12 months.


Dyne Therapeutics Inc is a biotechnology company that focuses on developing targeted therapies for patients with serious muscle diseases. They utilize their proprietary technology platform to deliver oligonucleotide therapeutics directly to muscle tissue, aiming to restore muscle function and improve overall patient outcomes.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 2,526.387 mill. $ - mill. $ -208.126 mill. 61 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 2,526.387 mill.


$ - mill.


$ -208.126 mill.

Employees Shares Outstanding P/E

1,679


61 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



JANX

$44.23

$31.6500 251.59%
Last 12 Months


JANX

$44.23

$31.6500 251.59%



Janux Therapeutics Inc

Janux Therapeutics Inc stock improved 251.59% over the past 12 months.


Janux Therapeutics Inc is a biotechnology company that focuses on developing and commercializing innovative cancer treatments. Their business model revolves around leveraging their expertise in immunotherapies and bispecific antibody platforms to create novel therapies that target tumor cells and activate the patient*s immune system. By partnering with pharmaceutical companies and conducting clinical trials, they aim to bring effective and personalized cancer treatments to market.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 2,021.694 mill. $ 8.467 mill. $ -62.600 mill. 46 mill. - Y/Y 38.83 %
Market Cap. Revenues TTM Net Income TTM

$ 2,021.694 mill.


$ 8.467 mill.


$ -62.600 mill.

Employees Shares Outstanding P/E

-


46 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 38.83 %


MRQ Y/Y - %



SLN

$20.6

$14.6300 245.06%
Last 12 Months


SLN

$20.6

$14.6300 245.06%



Silence Therapeutics Plc

Silence Therapeutics Plc shares improved 245.06% over the past 12 months.


Silence Therapeutics Plc is a biomedical company that specializes in the discovery, development, and commercialization of innovative RNA-based therapeutics. They employ a business model focused on leveraging their proprietary technology to develop a pipeline of therapeutics targeting various diseases with high unmet medical needs. Through strategic partnerships and licensing agreements, they aim to deliver transformative RNA-based treatments to patients globally.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ - mill. $ 17.501 mill. $ -40.489 mill. - mill. - Y/Y 40.97 %
Market Cap. Revenues TTM Net Income TTM

$ - mill.


$ 17.501 mill.


$ -40.489 mill.

Employees Shares Outstanding P/E

-


- mill.


-

Revenue Growth Income Growth

MRQ Y/Y 40.97 %


MRQ Y/Y - %



LEXX

$2.79

$1.9600 236.14%
Last 12 Months


LEXX

$2.79

$1.9600 236.14%



Lexaria Bioscience Corp

Lexaria Bioscience Corp shares went up 236.14% over the past 12 months.


Lexaria Bioscience Corp is a biotechnology company that focuses on enhancing the bioavailability and effectiveness of certain active compounds through its patented DehydraTECH technology. The company licenses its technology to third-party partners or collaborates with them to develop products in various sectors such as pharmaceuticals, nutraceuticals, and consumer packaged goods. Lexaria generates revenue through licensing fees, royalties from its partners, and potential product sales through its subsidiary, Lexaria Nicotine LLC.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 38.656 mill. $ -3.053 mill. $ -6.640 mill. 14 mill. - Y/Y -9.82 %
Market Cap. Revenues TTM Net Income TTM

$ 38.656 mill.


$ -3.053 mill.


$ -6.640 mill.

Employees Shares Outstanding P/E

-


14 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -9.82 %


MRQ Y/Y - %



LRMR

$10.49

$7.2500 223.77%
Last 12 Months


LRMR

$10.49

$7.2500 223.77%



Larimar Therapeutics Inc

Larimar Therapeutics Inc stock improved 223.77% over the past 12 months.


Larimar Therapeutics Inc*s business model revolves around the development and commercialization of innovative therapeutics for the treatment of rare and serious genetic diseases.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 460.550 mill. $ - mill. $ -33.381 mill. 44 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 460.550 mill.


$ - mill.


$ -33.381 mill.

Employees Shares Outstanding P/E

110


44 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



DERM

$5.66

$3.8900 219.77%
Last 12 Months


DERM

$5.66

$3.8900 219.77%



Journey Medical Corporation

Journey Medical Corporation shares went up 219.77% over the past 12 months.


Journey Medical Corporation is a pharmaceutical and medical device company that specializes in developing and commercializing innovative products for dermatology and aesthetics. Their business model revolves around conducting research and development to create new products, acquiring the necessary regulatory approvals, and partnering with healthcare professionals to effectively distribute and market these products. By focusing on dermatology and aesthetics, Journey Medical Corporation aims to address unmet medical needs and provide cutting-edge solutions to improve patient outcomes in these fields.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 111.827 mill. $ 79.998 mill. $ -4.159 mill. 20 mill. - Y/Y 6.69 %
Market Cap. Revenues TTM Net Income TTM

$ 111.827 mill.


$ 79.998 mill.


$ -4.159 mill.

Employees Shares Outstanding P/E

-


20 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 6.69 %


MRQ Y/Y - %



MREO

$4.15

$2.8400 216.79%
Last 12 Months


MREO

$4.15

$2.8400 216.79%



Mereo Biopharma Group Plc

Mereo Biopharma Group Plc stock went up 216.79% over the past 12 months.


Mereo Biopharma Group Plc*s business model focuses on the development and commercialization of innovative therapeutics for rare diseases.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 2,365.223 mill. $ - mill. $ -34.196 mill. 570 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 2,365.223 mill.


$ - mill.


$ -34.196 mill.

Employees Shares Outstanding P/E

46


570 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



NKTX

$6.51

$4.4450 215.25%
Last 12 Months


NKTX

$6.51

$4.4450 215.25%



Nkarta Inc

Nkarta Inc stock went up 215.25% over the past 12 months.


Nkarta Inc is a biotechnology company with a business model centered on developing and commercializing engineered natural killer (NK) cell therapies for cancer patients. By utilizing proprietary technologies and expertise in genetic engineering, the company aims to enhance the therapeutic potential of NK cells and address unmet needs in the field of oncology. Nkarta Inc focuses on research, development, and production of these advanced cell therapies, collaborating with partners and regulators to bring innovative treatments to patients.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 319.399 mill. $ - mill. $ -122.329 mill. 49 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 319.399 mill.


$ - mill.


$ -122.329 mill.

Employees Shares Outstanding P/E

-


49 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



RYTM

$50.02

$33.9700 211.65%
Last 12 Months


RYTM

$50.02

$33.9700 211.65%



Rhythm Pharmaceuticals inc

Rhythm Pharmaceuticals Inc shares went up 211.65% over the past 12 months.


Rhythm Pharmaceuticals Inc*s business model focuses on developing and commercializing therapies for rare genetic disorders that result in unmet medical needs.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 3,008.381 mill. $ 79.161 mill. $ -284.417 mill. 60 mill. - Y/Y 62.15 %
Market Cap. Revenues TTM Net Income TTM

$ 3,008.381 mill.


$ 79.161 mill.


$ -284.417 mill.

Employees Shares Outstanding P/E

-


60 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 62.15 %


MRQ Y/Y - %



EWTX

$22.42

$14.9500 200.13%
Last 12 Months


EWTX

$22.42

$14.9500 200.13%



Edgewise Therapeutics inc

Edgewise Therapeutics Inc stock increased 200.13% over the past 12 months.


Edgewise Therapeutics Inc*s business model revolves around developing and commercializing small molecule therapies to treat rare muscle disorders.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 1,963.259 mill. $ - mill. $ -105.850 mill. 88 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 1,963.259 mill.


$ - mill.


$ -105.850 mill.

Employees Shares Outstanding P/E

14


88 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



XRTX

$1.95

$1.2906 195.72%
Last 12 Months


XRTX

$1.95

$1.2906 195.72%



Xortx Therapeutics inc

Xortx Therapeutics Inc stock improved 195.72% over the past 12 months.


Xortx Therapeutics Inc*s business model focuses on the development and commercialization of innovative therapies for the treatment of kidney diseases.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 3.864 mill. $ 0.919 mill. $ -2.158 mill. 2 mill. - Y/Y 406.91 %
Market Cap. Revenues TTM Net Income TTM

$ 3.864 mill.


$ 0.919 mill.


$ -2.158 mill.

Employees Shares Outstanding P/E

-


2 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 406.91 %


MRQ Y/Y - %



TNGX

$9.96

$6.5100 188.70%
Last 12 Months


TNGX

$9.96

$6.5100 188.70%



Tango Therapeutics Inc

Tango Therapeutics Inc stock improved 188.70% over the past 12 months.


Tango Therapeutics Inc is a biotechnology company that focuses on developing cancer therapies using DNA sequencing and computational biology. Their business model revolves around discovering and developing precision medicines by leveraging their expertise in genomics and biology to target specific cancer vulnerabilities.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 966.451 mill. $ 37.507 mill. $ -100.041 mill. 97 mill. - Y/Y 55.09 %
Market Cap. Revenues TTM Net Income TTM

$ 966.451 mill.


$ 37.507 mill.


$ -100.041 mill.

Employees Shares Outstanding P/E

-


97 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 55.09 %


MRQ Y/Y - %



MTEM

$1.37

$0.8600 168.63%
Last 12 Months


MTEM

$1.37

$0.8600 168.63%



Molecular Templates Inc

Molecular Templates Inc stock went up 168.63% over the past 12 months.


Molecular Templates Inc*s business model involves the development and commercialization of innovative biologic drugs based on their proprietary engineered toxin bodies (ETBs) platform.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 9.612 mill. $ 62.346 mill. $ -18.313 mill. 7 mill. 2.80 Y/Y 161.46 %
Market Cap. Revenues TTM Net Income TTM

$ 9.612 mill.


$ 62.346 mill.


$ -18.313 mill.

Employees Shares Outstanding P/E

45


7 mill.


2.80

Revenue Growth Income Growth

MRQ Y/Y 161.46 %


MRQ Y/Y -97.68 %



XTLB

$2.4801

$1.5451 165.25%
Last 12 Months


XTLB

$2.4801

$1.5451 165.25%



Xtl Biopharmaceuticals Ltd

Xtl Biopharmaceuticals Ltd shares went up 165.25% over the past 12 months.


Xtl Biopharmaceuticals Ltd*s business model revolves around developing and commercializing innovative biopharmaceutical products.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 1,351.422 mill. $ - mill. $ 0.000 mill. 545 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 1,351.422 mill.


$ - mill.


$ 0.000 mill.

Employees Shares Outstanding P/E

-


545 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



CRNX

$53.67

$33.1900 162.06%
Last 12 Months


CRNX

$53.67

$33.1900 162.06%



Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals Inc stock improved 162.06% over the past 12 months.


Crinetics Pharmaceuticals Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. They primarily generate revenue through the sale of their developed drugs and potential partnerships with other pharmaceutical companies.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 3,048.885 mill. $ 4.722 mill. $ -199.423 mill. 57 mill. - Y/Y -24.45 %
Market Cap. Revenues TTM Net Income TTM

$ 3,048.885 mill.


$ 4.722 mill.


$ -199.423 mill.

Employees Shares Outstanding P/E

-


57 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -24.45 %


MRQ Y/Y - %



PRAX

$50.88

$30.9300 155.04%
Last 12 Months


PRAX

$50.88

$30.9300 155.04%



Praxis Precision Medicines Inc

Praxis Precision Medicines Inc stock increased 155.04% over the past 12 months.


Praxis Precision Medicines Inc*s business model revolves around developing precision medicines for the treatment of various central nervous system (CNS) disorders.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 707.455 mill. $ 2.195 mill. $ -125.375 mill. 14 mill. - Y/Y -36.90 %
Market Cap. Revenues TTM Net Income TTM

$ 707.455 mill.


$ 2.195 mill.


$ -125.375 mill.

Employees Shares Outstanding P/E

-


14 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -36.90 %


MRQ Y/Y - %



MOR

$18.8

$11.2400 148.68%
Last 12 Months


MOR

$18.8

$11.2400 148.68%



Morphosys Ag

Morphosys Ag stock increased 148.68% over the past 12 months.


Morphosys Ag*s business model revolves around the development and commercialization of therapeutic antibodies.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 645.080 mill. $ 266.872 mill. $ -212.502 mill. 34 mill. - Y/Y -14.37 %
Market Cap. Revenues TTM Net Income TTM

$ 645.080 mill.


$ 266.872 mill.


$ -212.502 mill.

Employees Shares Outstanding P/E

434


34 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -14.37 %


MRQ Y/Y - %



NKTR

$1.42

$0.8464 147.56%
Last 12 Months


NKTR

$1.42

$0.8464 147.56%



Nektar Therapeutics

Nektar Therapeutics stock went up 147.56% over the past 12 months.


Nektar Therapeutics operates under a business model focused on developing and commercializing innovative medicines. The company*s approach involves utilizing its proprietary technology platforms to create novel therapeutic candidates and establish partnerships with pharmaceutical and biotechnology firms for clinical development and commercialization. Nektar Therapeutics aims to bring transformative therapies to market that address significant unmet medical needs.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 270.377 mill. $ 88.260 mill. $ -293.665 mill. 190 mill. - Y/Y 2.20 %
Market Cap. Revenues TTM Net Income TTM

$ 270.377 mill.


$ 88.260 mill.


$ -293.665 mill.

Employees Shares Outstanding P/E

725


190 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 2.20 %


MRQ Y/Y - %



HRTX

$3.24

$1.9300 147.33%
Last 12 Months


HRTX

$3.24

$1.9300 147.33%



Heron Therapeutics Inc

Heron Therapeutics Inc shares went up 147.33% over the past 12 months.


Heron Therapeutics Inc is a biotechnology company that focuses on developing innovative treatments for patients suffering from pain and other serious conditions. Their business model revolves around researching, developing, and commercializing novel therapeutics utilizing their proprietary technology platforms. By collaborating with healthcare providers and other industry partners, Heron Therapeutics aims to bring effective and safe solutions to patients in need.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 469.768 mill. $ 122.631 mill. $ -119.704 mill. 145 mill. - Y/Y 17.58 %
Market Cap. Revenues TTM Net Income TTM

$ 469.768 mill.


$ 122.631 mill.


$ -119.704 mill.

Employees Shares Outstanding P/E

336


145 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 17.58 %


MRQ Y/Y - %



ADCT

$3.82

$2.2700 146.45%
Last 12 Months


ADCT

$3.82

$2.2700 146.45%



Adc Therapeutics Sa

Adc Therapeutics Sa shares increased 146.45% over the past 12 months.


Adc Therapeutics Sa is a biotechnology company that focuses on the development and commercialization of antibody drug conjugates (ADCs) for the treatment of cancer. Their business model revolves around using their proprietary pyrrolobenzodiazepine (PBD) technology to create highly potent ADCs that selectively target cancer cells while minimizing damage to healthy cells. They aim to collaborate with global pharmaceutical companies to co-develop and potentially commercialize their ADC candidates, generating revenue through licensing agreements and milestone payments.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 315.350 mill. $ 297.519 mill. $ -442.459 mill. 83 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 315.350 mill.


$ 297.519 mill.


$ -442.459 mill.

Employees Shares Outstanding P/E

9,050


83 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



ELYM

$7.22

$4.2300 141.47%
Last 12 Months


ELYM

$7.22

$4.2300 141.47%



Eliem Therapeutics Inc

Eliem Therapeutics Inc stock increased 141.47% over the past 12 months.


Eliem Therapeutics Inc*s business model revolves around developing and commercializing innovative therapeutic solutions for various medical conditions.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 195.453 mill. $ - mill. $ -39.240 mill. 27 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 195.453 mill.


$ - mill.


$ -39.240 mill.

Employees Shares Outstanding P/E

-


27 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



THRD

$12.98

$7.6000 141.26%
Last 12 Months


THRD

$12.98

$7.6000 141.26%



Third Harmonic Bio Inc

Third Harmonic Bio Inc shares went up 141.26% over the past 12 months.


Third Harmonic Bio Inc*s business model centers around developing and commercializing innovative therapeutic solutions through the utilization of bioinformatics and genomics.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 515.174 mill. $ - mill. $ 15.783 mill. 40 mill. 32.45 Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 515.174 mill.


$ - mill.


$ 15.783 mill.

Employees Shares Outstanding P/E

-


40 mill.


32.45

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y -10.51 %




 1 Day   Week  Current Month of July  30 Days 
Current Quarter Q3 of 2024  90 Days    Ytd    12 Months 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com